DaltonTx lands £4M to advance the intelligence backbone of drug discovery

UK-based technology company DaltonTx has exited stealth and completed a £4 million seed financing round. Backed by Redalpine, IQ Capital Partners, and Seedcamp, with additional support from Oxford University Innovation, DaltonTx will use this funding to redefine how technology transforms drug discovery.

Pharma has a rare chance to make discovery faster and more effective with AI, but creating adaptive platforms demands years of engineering and deep scientific know-how. DaltonTx addresses this gap with a disease- and technology-agnostic platform that plugs into pharma, biotech, and CRO workflows, giving teams immediate access to AI-enabled discovery instead of building it in-house.

DaltonTx was founded by Dr Garry Pairaudeau, Adrian Rossall, Dr Anthony Bradley, and Professor Charlotte Deane MBE, bringing decades of real-world experience in drug discovery, machine learning, and software engineering.

Built by scientists for scientists, DaltonTx goes beyond predictive modelling to power the entire discovery loop, from raw data and model training to molecular design, synthesis, and decision-making. It’s not merely predictive, it’s adaptive: a reasoning engine that learns from every scientist, model, and experiment to improve outcomes continuously.

DaltonTx’s platform is purpose-built for both small molecules and biologics, making it well-suited to the most complex R&D pipelines. It also enables collaborative intelligence, allowing scientists to work with an engine that iterates and learns, combining human insight with machine learning in real time.

As explained by Dr Garry Pairaudeau, the company was created to change the status quo. It tackles high-impact problems with adaptive, AI-enabled systems that slot into scientific workflows, learn from every experiment, and equip organisations with durable AI capability.

The funds will be used to build adaptive, AI-enabled discovery platforms that reshape the economics, timelines, and outcomes of R&D so breakthrough medicines reach patients faster.